U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Biliary Tract Carcinoma

MedGen UID:
1783813
•Concept ID:
C5446939
•
Neoplastic Process

Definition

Biliary tract carcinoma that is not amenable to surgical resection. [from NCI]

Professional guidelines

PubMed

Treatment of biliary tract carcinoma over the last 30 years.
Midorikawa Y
Biosci Trends 2022 Jul 20;16(3):189-197. Epub 2022 Jun 23 doi: 10.5582/bst.2022.01267. PMID: 35732436
Endoscopic deployment of multiple JOSTENT SelfX is effective and safe in treatment of malignant hilar biliary strictures.
Kawamoto H, Tsutsumi K, Harada R, Fujii M, Kato H, Hirao K, Kurihara N, Nakanishi T, Mizuno O, Ishida E, Ogawa T, Fukatsu H, Sakaguchi K
Clin Gastroenterol Hepatol 2008 Apr;6(4):401-8. Epub 2008 Mar 7 doi: 10.1016/j.cgh.2007.12.036. PMID: 18328793

Recent clinical studies

Etiology

Management of occluded metallic stents in malignant hilar biliary stricture.
Fujii M, Kawamoto H, Tsutsumi K, Kato H, Hirao K, Kurihara N, Mizuno O, Ishida E, Ogawa T, Fukatsu H, Yamamoto K
Hepatogastroenterology 2013 May;60(123):447-51. doi: 10.5754/hge12679. PMID: 23108079
Endoscopic deployment of multiple JOSTENT SelfX is effective and safe in treatment of malignant hilar biliary strictures.
Kawamoto H, Tsutsumi K, Harada R, Fujii M, Kato H, Hirao K, Kurihara N, Nakanishi T, Mizuno O, Ishida E, Ogawa T, Fukatsu H, Sakaguchi K
Clin Gastroenterol Hepatol 2008 Apr;6(4):401-8. Epub 2008 Mar 7 doi: 10.1016/j.cgh.2007.12.036. PMID: 18328793
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Taïeb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T, Clavero-Fabri MC, Vaillant JN, Rougier P, Ducreux M
Ann Oncol 2002 Aug;13(8):1192-6. doi: 10.1093/annonc/mdf201. PMID: 12181241

Diagnosis

Management of occluded metallic stents in malignant hilar biliary stricture.
Fujii M, Kawamoto H, Tsutsumi K, Kato H, Hirao K, Kurihara N, Mizuno O, Ishida E, Ogawa T, Fukatsu H, Yamamoto K
Hepatogastroenterology 2013 May;60(123):447-51. doi: 10.5754/hge12679. PMID: 23108079
Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.
Brunner TB, Eccles CL
Strahlenther Onkol 2010 Dec;186(12):672-80. Epub 2010 Nov 30 doi: 10.1007/s00066-010-2161-y. PMID: 21136029

Therapy

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Tella SH, Foster N, Qian S, Nguyen T, Borad MJ, McWilliams RR, Alberts SR, Wee Ma W, Chakrabarti S, Fruth B, Wessling J, Hartgers M, Washburn L, Fernandez-Zapico ME, Hogenson TL, Pitot H, Jin Z, Mahipal A
Oncologist 2023 Oct 3;28(10):917-e966. doi: 10.1093/oncolo/oyad144. PMID: 37339254Free PMC Article
Treatment of biliary tract carcinoma over the last 30 years.
Midorikawa Y
Biosci Trends 2022 Jul 20;16(3):189-197. Epub 2022 Jun 23 doi: 10.5582/bst.2022.01267. PMID: 35732436
Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.
Brunner TB, Eccles CL
Strahlenther Onkol 2010 Dec;186(12):672-80. Epub 2010 Nov 30 doi: 10.1007/s00066-010-2161-y. PMID: 21136029
A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.
Kobayashi K, Tsuji A, Morita S, Horimi T, Shirasaka T, Kanematsu T
BMC Cancer 2006 May 6;6:121. doi: 10.1186/1471-2407-6-121. PMID: 16677397Free PMC Article
A phase II study of cisplatin in patients with biliary tract carcinoma.
Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, Iwasaki M, Furuse J, Yoshino M
Oncology 1994 Nov-Dec;51(6):515-7. doi: 10.1159/000227396. PMID: 7970496

Prognosis

A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.
Kobayashi K, Tsuji A, Morita S, Horimi T, Shirasaka T, Kanematsu T
BMC Cancer 2006 May 6;6:121. doi: 10.1186/1471-2407-6-121. PMID: 16677397Free PMC Article
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Taïeb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T, Clavero-Fabri MC, Vaillant JN, Rougier P, Ducreux M
Ann Oncol 2002 Aug;13(8):1192-6. doi: 10.1093/annonc/mdf201. PMID: 12181241

Clinical prediction guides

Endoscopic 3-branched partial stent-in-stent deployment of metallic stents in high-grade malignant hilar biliary stricture (with videos).
Kawamoto H, Tsutsumi K, Fujii M, Harada R, Kato H, Hirao K, Kurihara N, Nakanishi T, Mizuno O, Ishida E, Ogawa T, Fukatsu H, Sakaguchi K
Gastrointest Endosc 2007 Nov;66(5):1030-7. doi: 10.1016/j.gie.2007.06.055. PMID: 17963891
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Taïeb J, Mitry E, Boige V, Artru P, Ezenfis J, Lecomte T, Clavero-Fabri MC, Vaillant JN, Rougier P, Ducreux M
Ann Oncol 2002 Aug;13(8):1192-6. doi: 10.1093/annonc/mdf201. PMID: 12181241

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...